Round Table Discussion: Aesthetic Treatment Considerations for the Perimenopausal & Menopausal Patient.

Publisher: Blackwell Science Country of Publication: England NLM ID: 101130964 Publication Model: Print Cited Medium: Internet ISSN: 1473-2165 (Electronic) Linking ISSN: 14732130 NLM ISO Abbreviation: J Cosmet Dermatol Subsets: MEDLINE

Original Publication: Oxford, UK : Blackwell Science, c2002-

Perimenopause*/physiology ; Menopause*/physiology ; Cosmetic Techniques*/standards; Skin Aging/drug effects ; Estrogen Replacement Therapy/methods ; Humans ; Female ; Middle Aged

Background: Menopause is a normal feature of the female aging process that commonly occurs during the 6th decade of life. During perimenopause, many negative effects begin to occur affecting the skin that are associated with decreasing production of estrogen, progesterone, and testosterone. Estrogen supports the extracellular matrix, collagen production, and dermal blood supply, while progesterone promotes extracellular matrix formation, dermal blood supply, and dermal water retention. Decreased testosterone impacts cutaneous blood supply and sebum production, causing skin dryness.
Aims: The primary objective of the following consensus roundtable was to discuss best practices for aesthetic providers when treating patients with perimenopausal and menopause-related skin conditions.
Patients/methods: A roundtable discussion was held by several notable experts in their field during a special edition of the Thriving in Diversity webinar series on Friday, June 13, 2025. The discussion included a gynecologist, a plastic surgeon, and two dermatologists who provided their clinical experience and consensus recommendations for treating perimenopausal and menopausal patients.
Results: Numerous therapies are available to treat patients with perimenopausal and menopause-related skin conditions. These include hormone replacement therapy (HRT), topical estrogen therapy, topical retinoids, topical cosmeceuticals (moisturizers, signal peptides, growth factors, exosomes), dermal injectables and biostimulators, and energy-based treatments, each with varying beneficial effects. The experts in this panel find that hormone replacement therapy, topical estrogen, injectable poly-L-lactic acid, injectable hyaluronic acid, and carbon dioxide laser resurfacing are the most effective interventions for treating hormone-related skin changes.
Conclusions: Although menopause ultimately affects all women and is likely to produce unwanted effects including undesirable aesthetic changes, numerous treatments are available to treat or mitigate these effects.
(© 2025 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)

Aesthet Surg J. 2022 Sep 14;42(10):1185-1193. (PMID: 35689936)
J Cosmet Dermatol. 2026 Jan;25(1):e70626. (PMID: 41461019)
Nutrients. 2023 Sep 23;15(19):. (PMID: 37836398)
J Am Acad Dermatol. 2001 Sep;45(3 Suppl):S116-24. (PMID: 11511861)
J Biol Chem. 1993 May 15;268(14):9941-4. (PMID: 8486721)
J Clin Aesthet Dermatol. 2017 May;10(5):31-35. (PMID: 28670356)
J Drugs Dermatol. 2022 Nov 1;21(11):1185-1190. (PMID: 36342739)
Menopause. 2022 Jul 1;29(7):767-794. (PMID: 35797481)
Aesthet Surg J. 2022 Mar 15;42(4):327-339. (PMID: 34724035)
Trends Endocrinol Metab. 2012 Nov;23(11):576-81. (PMID: 22595550)
Dermatol Surg. 2018 Nov;44 Suppl 1:S32-S41. (PMID: 30358631)
J Clin Aesthet Dermatol. 2025 Apr;18(4):33-40. (PMID: 40256340)
Planta Med. 2008 Oct;74(13):1656-65. (PMID: 18843590)
Biomolecules. 2023 Nov 04;13(11):. (PMID: 38002296)
Dermatoendocrinol. 2013 Apr 1;5(2):264-70. (PMID: 24194966)
J Cosmet Dermatol. 2021 Aug;20(8):2425-2430. (PMID: 33977643)
BMC Nurs. 2022 Aug 23;21(1):233. (PMID: 35999542)
Am J Clin Dermatol. 2016 Jun;17(3):265-76. (PMID: 26969582)
Clin Nurs Res. 2000 Feb;9(1):6-23; discussion 24-6. (PMID: 11271048)
Lasers Surg Med. 2025 Jan;57(1):15-26. (PMID: 39434507)
J Drugs Dermatol. 2014 Dec;13(12):1467-72. (PMID: 25607790)
Clin Cosmet Investig Dermatol. 2012;5:147-58. (PMID: 23071398)
Clin Interv Aging. 2006;1(4):327-48. (PMID: 18046911)
Aesthet Surg J. 2021 May 18;41(Suppl 1):S31-S38. (PMID: 34002771)
Menopause. 2024 Oct 1;31(10):926-939. (PMID: 39081162)
Dermatol Ther (Heidelb). 2025 Jul;15(7):1681-1703. (PMID: 40329055)
An Bras Dermatol. 2017 May-Jun;92(3):356-362. (PMID: 29186248)
J Obstet Gynaecol India. 2022 Aug;72(4):322-329. (PMID: 35923503)
Circulation. 2023 Feb 14;147(7):597-610. (PMID: 36780393)
Cureus. 2023 Aug 6;15(8):e43053. (PMID: 37680393)
Dermatol Surg. 2023 Jan 1;49(1):42-47. (PMID: 36533795)
J Cosmet Dermatol. 2024 Sep;23(9):2905-2917. (PMID: 39073288)
Dermatol Surg. 2016 Nov;42(11):1261-1265. (PMID: 27598446)
J Drugs Dermatol. 2018 Nov 01;17(11):1186 - 1189. (PMID: 30500138)
Cancer J. 2022 May-Jun 01;28(3):208-223. (PMID: 35594469)
J Clin Med. 2023 Feb 07;12(4):. (PMID: 36835861)
Plast Reconstr Surg Glob Open. 2023 Jun 12;11(6):e5051. (PMID: 37313480)
J Cosmet Dermatol. 2021 Jun;20(6):1634-1642. (PMID: 33773034)
J Drugs Dermatol. 2025 Jan 1;24(1):34-40. (PMID: 39761144)
Dermatol Surg. 2024 Dec 1;50(12):1155-1162. (PMID: 39503574)
Plast Reconstr Surg Glob Open. 2020 Mar 27;8(3):e2723. (PMID: 32537370)
Dermatol Surg. 2024 Nov 1;50(11S):S166-S171. (PMID: 39480040)
Obstet Gynecol. 2023 Nov 1;142(5):1266-1273. (PMID: 37856860)
J Drugs Dermatol. 2024 Jan 1;23(1):1297-1305. (PMID: 38206151)
Gels. 2023 Jul 28;9(8):. (PMID: 37623069)
Molecules. 2024 Dec 07;29(23):. (PMID: 39683947)
Skin Res Technol. 2023 Jul;29(7):e13349. (PMID: 37522490)
Br J Gen Pract. 2020 Mar 26;70(693):203-204. (PMID: 32217602)
Int J Cosmet Sci. 2005 Jun;27(3):155-60. (PMID: 18492182)
Clin Cosmet Investig Dermatol. 2019 Oct 24;12:791-798. (PMID: 31749628)
J Cosmet Dermatol. 2018 Jun;17(3):282-288. (PMID: 29436770)
Post Reprod Health. 2024 Jun;30(2):85-94. (PMID: 38379168)
Dermatol Surg. 2014 Dec;40 Suppl 12:S168-73. (PMID: 25417570)
J Cosmet Dermatol. 2023 Jul;22(7):2023-2039. (PMID: 37222303)
Int J Cosmet Sci. 2017 Feb;39(1):56-65. (PMID: 27261203)
Maturitas. 1992 Oct;15(2):113-9. (PMID: 1345134)
Dermatol Surg. 2014 Dec;40 Suppl 12:S164-7. (PMID: 25417569)
Climacteric. 2005 Jun;8(2):110-23. (PMID: 16096167)
Cutis. 2016 Feb;97(2):E16-23. (PMID: 26919507)
Int J Womens Dermatol. 2019 Mar 15;5(2):85-90. (PMID: 30997378)
J Extracell Vesicles. 2015 May 14;4:27066. (PMID: 25979354)
Menopause. 2022 Jan 10;29(3):344-350. (PMID: 35013059)
J Cosmet Dermatol. 2014 Mar;13(1):44-51. (PMID: 24641605)
J Womens Health (Larchmt). 2013 Nov;22(11):983-90. (PMID: 24083674)
Clin Cosmet Investig Dermatol. 2015 Feb 05;8:47-52. (PMID: 25709486)
J Drugs Dermatol. 2012 Nov;11(11):1316-20. (PMID: 23135081)
J Clin Aesthet Dermatol. 2024 Oct;17(10):45-53. (PMID: 39445324)
Health Sci Rep. 2021 Oct 05;4(4):e399. (PMID: 34632098)
Int J Cosmet Sci. 2021 Apr;43(2):123-130. (PMID: 33354795)
BMC Womens Health. 2015 Aug 13;15:58. (PMID: 26271251)
Clin Cosmet Investig Dermatol. 2022 Aug 19;15:1695-1709. (PMID: 36017417)
Maturitas. 1994 Oct;19(3):211-23. (PMID: 7799828)
Ann Dermatol. 2023 Dec;35(6):424-431. (PMID: 38086356)
Health Sci Rep. 2024 Jan 21;7(1):e1743. (PMID: 38260185)
J Cosmet Dermatol. 2025 Jan;24(1):e16766. (PMID: 39764639)
Dermatol Surg. 2019 May;45(5):718-724. (PMID: 30741790)
Arch Dermatol Res. 2022 Nov;314(9):823-838. (PMID: 34609598)
Dermatol Surg. 2022 Aug 1;48(8):862-865. (PMID: 35580250)

Keywords: estrogen; estrogen‐deficient skin; menopause; perimenopause; roundtable discussion; therapeutic options

Date Created: 20251229 Date Completed: 20251229 Latest Revision: 20260102

20260130

PMC12747467

10.1111/jocd.70626

41461019